NANO MRNA CO.,LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 174 JPY | -2.79% |
|
-3.33% | -8.42% |
| 2023 | NANO MRNA, Kao Tie Up to Develop mRNA Therapies for Allergic Diseases | MT |
| 2023 | NANO MRNA Co., Ltd. and Kao Corporation Agree a Comprehensive Collaborative Research for mRNA Drug Discovery | CI |
| Sales * | - | Sales 1 * | - | Capitalization | 16.83B 109M |
|---|---|---|---|---|---|
| Net income * | - | Net income 1 * | - | EV / Sales * | - |
| Net cash position * | - 0 | Net cash position 1 * | - 0 | EV / Sales 1 * | - |
| P/E ratio * |
-
| P/E ratio 1 * |
-
| Employees | 17 |
| Yield * |
-
| Yield 1 * |
-
| Free-Float | 93.47% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.79% | ||
| 1 week | -3.33% | ||
| Current month | -5.95% | ||
| 1 month | -3.33% | ||
| 3 months | -5.43% | ||
| 6 months | -0.57% | ||
| Current year | -8.42% |
1 week
172.00
186.00
1 month
172.00229.00
Current year
169.00229.00
1 year
163.00259.00
3 years
163.00342.00
5 years
163.00752.00
10 years
163.002 156.00
| Managers | Title | Age | Since |
|---|---|---|---|
Shiro Akinaga
CEO | Chief Executive Officer | 67 | 20-05-31 |
Koji Fujimoto
DFI | Director of Finance/CFO | 51 | 02-10-31 |
| Comptroller/Controller/Auditor | 61 | 14-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Satoru Iino
BRD | Director/Board Member | 58 | 12-02-29 |
Kazunori Kataoka
FOU | Founder | 73 | 96-06-13 |
Teruo Okano
FOU | Founder | 75 | 96-06-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 174 | -2.79% | 531,900 |
| 24-04-18 | 179 | +1.70% | 166,800 |
| 24-04-17 | 176 | -1.12% | 316,300 |
| 24-04-16 | 178 | -3.78% | 545,100 |
| 24-04-15 | 185 | +2.78% | 397,600 |
Delayed Quote Japan Exchange, April 19, 2024 at 02:00 am EDT
More quotes
Nano Mrna Co Ltd, formerly NanoCarrier Co Ltd, is mainly engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company develops businesses using the research and development of messenger ribonucleic acid (mRNA) medicine. The products under development are specialized in mRNA medicines. mRNA medicine is a medicine that prevents or treats diseases by administering artificially produced mRNA to the body and allowing the body to discover the protein encoded by the mRNA. Its pipeline includes RUNX1, the mRNA drug pipeline, non-mRNA drug pipeline, Comrex otological liquid 1.5%, NC-6100, TUG1, and others.
Calendar
2024-05-13
- Q4 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -8.42% | 81.49M | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- 4571 Stock
